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Abstract
The mechanisms underlying the proapoptotic effect of the chemotherapeutic agent, cisplatin, are largely undefined.
Understanding themechanisms regulating cisplatin cytotoxicitymay uncover strategies to enhance the efficacy of this
important therapeutic agent. This study evaluates the role of activating transcription factor 3 (ATF3) as a mediator of
cisplatin-induced cytotoxicity. Cytotoxic doses of cisplatin and carboplatin treatments consistently induced ATF3 ex-
pression in five tumor-derived cell lines. Characterization of this induction revealed a p53, BRCA1, and integrated stress
response–independent mechanism, all previously implicated in stress-mediated ATF3 induction. Analysis of mitogen-
activated protein kinase (MAPK) pathway involvement in ATF3 induction by cisplatin revealed a MAPK-dependent
mechanism. Cisplatin treatment combined with specific inhibitors to each MAPK pathway (c-Jun N-terminal kinase,
extracellular signal-regulated kinase, and p38) resulted in decreasedATF3 induction at the protein level.MAPKpathway
inhibition led to decreased ATF3 messenger RNA expression and reduced cytotoxic effects of cisplatin as measured
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay. In A549 lung carcinoma cells,
targeting ATF3 with specific small hairpin RNA also attenuated the cytotoxic effects of cisplatin. Similarly, ATF3−/−
murine embryonic fibroblasts (MEFs) were shown to be less sensitive to cisplatin-induced cytotoxicity compared with
ATF3+/+ MEFs. This study identifies cisplatin as a MAPK pathway–dependent inducer of ATF3, whose expression
influences cisplatin’s cytotoxic effects.
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Introduction
cis-Diamminedichloroplatinum(II) (cisplatin) is among the most active
antitumor agent used in human chemotherapy. Cisplatin and its deriv-
ative, carboplatin, are widely used agents in various tumor types includ-
ing lung and ovarian cancers [1]. Acquired resistance and toxicities
associated with treatment are major impediments inhibiting their effi-
cacy [2]. Understanding the mechanisms regulating tumor cell cytotoxi-
city may uncover novel therapeutic strategies to enhance the efficacy
of these platinum-based chemotherapeutics. Cisplatin and carboplatin
are primarily considered as DNA-damaging anticancer drugs, forming
different types of bifunctional adducts in reaction with cellular DNA
[1]. Cisplatin and carboplatin become activated intracellularly by aquat-
ing one of two chloride-leaving groups and, subsequently, by covalently
binding to DNA, forming DNA adducts [3]. Carboplatin is a less toxic
compound with a more stable leaving group than chloride, which
lowers toxicity and reduces nephrotoxicity [4]. Efficacious treatments
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of carboplatin generally require up to 20-fold higher doses than cis-
platin and are tolerated because of its decreased toxicity [5]. The final
cellular outcome of DNA adduct formation is generally apoptotic cell
death, thought to occur through halting of cellular processes such as
replication and transcription, leading to prolonged G2 phase cell cycle
arrest and deregulation of signal transduction pathways involved in
growth, differentiation, and stress responses [1,3]. Cellular mechanisms of
resistance to platinum-based chemotherapeutics are multifactorial and
contribute to severe limitation in their use in clinical practice. They
include molecular events inhibiting drug-DNA interaction, such as
reduction in cisplatin accumulation inside cancer cells or inactivation
by thiol-containing species [2]. Other important mechanisms acting
downstream of the initial reaction of cisplatin with DNA include an
increase in adduct repair and a decrease in induction of apoptosis [2].
AlthoughDNA is the primary target of cisplatin and carboplatin activity,
gaps in our understanding of the process that translates cisplatin-
induced DNA damage into its therapeutically beneficial process of
apoptosis still remain. Two significant cellular pathways have been dem-
onstrated to play key roles in platin-induced apoptosis/cytotoxicity,
the mitogen-activated protein kinase (MAPK) cascades, and the tumor
suppressor p53 [6,7]. An understanding of the mode of action is indeed
desirable in refining therapeutic approaches that further enhance the
antitumor activity of platinum-based chemotherapeutics.
Activating transcription factor 3 (ATF3) is a member of the basic
region-leucine zipper proteins originally identified for their ability to
bind the cAMP-responsive element (ATF/CRE) site (TGACGTCA)
[8]. Whereas ATF3 messenger RNA (mRNA) and protein levels are
not detectable under basal conditions in most cells, a large body of evi-
dence shows that ATF3 is induced by a wide variety of stress-causing
agents including hypoxia, metabolic stress, and DNA damage [9].
ATF3 is also induced in times of physiological stress such as liver re-
generation [10], brain seizure [11], ischemia-reperfusion of the heart
[12], nerve damage [13,14], and UV damage where it plays a role in
maintaining genomic integrity [15]. ATF3 has been demonstrated
to play a role in apoptosis and proliferation, two cellular processes critical
for cancer progression [16–19]. ATF3 can either promote or suppress
these processes. For example, overexpression of ATF3 in the sense
orientation in colorectal cancer cells led to decreased focus formation
in vitro and reduced the size of mouse tumor xenografts in vivo [16].
Divergence in function of ATF3 between a proapoptotic and an anti-
apoptotic factor in cancer models is likely dependent on both cellular
model and state of malignancy [19,20]. ATF3 is also a member of the
activating protein 1 transcription factors that consist of homodimers
and heterodimers of the basic region-leucine zipper proteins that be-
long to the Jun (c-Jun, v-Jun, JunB, and JunD), Fos (c-Fos, v-Fos, FosB,
Fra1, and Fra2), and the related activating transcription factor (ATF2,
ATF3/LRF1, and B-ATF) subfamilies [21]. Activation of ATF3 by a
wide array of stress signaling pathways has been demonstrated, includ-
ing DNA repair pathway components p53 [22,23] and potentially
BRCA1 [17,24], the integrated stress response (ISR) that is principally
activated by hypoxia and metabolic stress [25], and the stress-induced
MAPK cascades (SAPK/c-Jun N-terminal kinase [JNK], and p38)
[26,27]. Of interest, p53 and the p38 MAPK pathway have also
been shown to play roles in regulating cisplatin-induced cytotoxi-
city [28,29].
In this study, we evaluated the potential of cisplatin to induce ATF3
and determined the pathway regulating this induction. Furthermore,
we determined the role of ATF3 as a mediator of the cytotoxic effects
of cisplatin.
Materials and Methods
Tissue Culture
The A549, PC3, HCC1937, and MCF-7 cell lines were obtained
from the American Type Culture Collection (Rockville, MD). Cell
lines SKOV-3 and A2780-cp were kindly provided by Dr Barbara
Vanderhyden, Ottawa Hospital Research Institute, Ottawa, Canada.
The murine embryonic fibroblasts (MEFs) used in this study were de-
rived from wild type and knockout mice from ATF3, ATF4, and ATF2
models kindly provided by D. Park (University of Ottawa, Ottawa,
Ontario, Canada) and L. Glimcher (Harvard Medical School, Boston,
MA). All cell lines were maintained in Dulbecco modified Eagle me-
dium (Media Services, Ottawa Regional Cancer Centre) supplemented
with 10% fetal bovine serum (Medicorp,Montreal,Canada) and100U/ml
penicillin and 100 μg/ml streptomycin (GIBCO, Burlington, Ontario,
Canada) of medium. Cells were exposed to cisplatin, carboplatin, and
taxol (provided by the pharmacy at the Ottawa Hospital Regional
Cancer Centre, Ottawa) alone or in combination with the p38 inhibi-
tor SB203580 (Calbiochem, Gibbstown, NJ), JNK inhibitor, JNK in-
hibitor II (SP600125; Calbiochem), or extracellular signal-regulated
kinase (ERK) inhibitorUO126 (Calbiochem)diluted inDMSO.Adeno-
virus p53wt and LacZ control were kindly provided byDr BruceMcKay
(Ottawa Hospital Research Institute).
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assay
In a 96-well flat-bottomed plate (Nunc, Naperville, IL), 5000 cells/
150 μl of cell suspension were used to seed each well. The cells were
incubated overnight to allow for cell attachment and recovery. Cells
were treated with indicated drugs and incubated for 48 hours at 37°C.
After treatment, 42 μl of a 5-mg/ml solution in PBS of the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tetra-
zolium substrate (Sigma, St Louis, MO) was added to each well and
incubated for ∼20 minutes at 37°C. The resulting violet formazan
precipitate was solubilized by the addition of 82 μl of a 0.01 M HCl/
10% SDS (Sigma) solution and was allowed to further incubate at
37°C overnight. The plates were then analyzed on a microplate reader
(MRX;Dynex Technologies,West Sussex, United Kingdom) at 570 nm
to determine the absorbance of the samples.
Flow Cytometry
Cells were plated at 1 × 106/10-cm dish and allowed to grow over-
night and subsequently treated with cisplatin for 48 hours. Single-cell
suspensions were labeled with 50 μg/ml propidium iodide (Sigma),
and approximately 106 cells in 1 ml were analyzed by flow cytometry.
Ten thousand cells were evaluated, and the percentage of cells in sub-2N
phase was determined using a software (Modfit LT; VeritySoftware
House, Topsham, ME).
Immunocytochemistry
MCF-7 and PC3 cells grown to 50% confluence were seeded on
2 × 15-cm plates/treatment/block with no treatment or with cisplatin
(8 μg/ml) for 24 hours. Cells were washed twice in PBS, harvested in
10 ml of PBS per plate, and combined with 20 ml of 20% neutral-
buffered formalin (Sigma). Cells were fixed at 4°C for 1 hour and spun
down at 1600 rpm for 10 minutes at 4°C, and cells were washed once
in PBS. Formalin-fixed cells were embedded in paraffin, cut into 5-μm
sections, and allowed to dry at room temperature overnight. Sections
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were deparaffinized by washing in toluene (3 × 5 minutes) followed
by absolute alcohol (2 × 1 minutes). Sections were washed with water
(5 minutes) followed by Tris-buffered saline (TBS) and loaded on the
intelliPAT FLX automated slide stainer (Davis Diagnostics, Brampton,
Canada). The automated slide stainer was programmed with the fol-
lowing treatments: 3% H2O2 in TBS for 10 minutes, rinsed in TBS for
5 minutes, blocked with universal blocking agent Background Sniper
(Biocare Medical, Brampton, Ontario, Canada) for 20 minutes at room
temperature, incubatedwith ATF3 antibody (1:200 dilution inDaVinci
universal diluent [Biocare Medical]) for 1 hour at room temperature,
rinsed with TBS for 5 minutes, incubated with universal mouse
probe (Mach 4 Universal Polymer Detection Kit; Biocare Medical)
for 5 minutes, rinsed with TBS for 5 minutes, incubated with Rabbit
HRP Polymere (Mach 4 Universal Polymer Detection Kit; Biocare
Medical) for 10 minutes at room temperature, rinsed with TBS, and
developed for 5 minutes with DAB RTU (Betazoid DABChromatogen
Kit; Biocare Medica) and rinsed with water. Slides were counterstained
in hematoxylin for 1 minute, washed in running water, 0.2% HCl in
70% alcohol for five dips, washed in running water for 1 minute,
dipped once in 2% aqueous saturated lithium carbonate, washed in
running water for 5 minutes, dehydrated in absolute alcohol, cleared
in toluene, andmounted on coverslips with Permount (Fisher Scientific,
Mississauga, Canada).
Transfection
MCF-7 cells plated at 3 × 105 in six-well plates were transfected with
2 μg of each p38 constructs (p38 wild type [WT], p38 dominant-
negative [DN], and p38 catalytically active [CA]; kindly provided by
Dr Douglas Gray, Ottawa Hospital Research Institute) using a transfec-
tion reagent (FuGENE HD; Roche, Mississauga, Ontario, Canada) as
per the manufacturer’s protocol. After 24 hours, the medium was re-
moved and replaced with medium containing cisplatin (10 μg/ml)
treatment alone or in combination with SB203580 (10 μM), and cells
were incubated for an additional 24 hours. Cells were then harvested
and analyzed by Western blot analysis.
Adenovirus Infection
PC3 cells were plated at 2.5 × 105 cells per well (six-well dish) and
infected with p53wt or LacZ control adenovirus (provided by Dr B.
McKay; Ottawa Hospital Research Institute) at 25 plaque-forming
units per milliliter per cell. After a 6-hour infection period, the medium
was removed from the cells and replaced with medium containing cis-
platin (10 μg/ml) or taxol (25 μM) for 24 hours. Cells were then har-
vested and analyzed by Western blot analysis as described below.
Design and Expression of Small Hairpin RNA
The two 19mer sequences targeting ATF3 mRNA are no. 1—5′-
GCCAAAGAATATTCCATTT-3′ and no. 2—5′-GGGAGGGCCTG-
CAGTGATT-3′ to pSuper vector from Oligoengine small hairpin
RNA (shRNA; no. 1: nucleotides 1524-1542 [GenBank accession
number NM_001030287]; no. 2: nucleotides 1270-1289 [GenBank
accession number NM_001030287]) target sequence. As controls,
we used the green fluorescent protein (GFP)–targeted oligonucleotide
5′CATGCGTCCACTCTTCCTC-3′ with accession number NC_
011521. These sequences were BLAST confirmed for specificity. The
forward and reverse synthetic 60-nt oligonucleotides (Integrated DNA
Technologies, Coralville, IA) were designed, annealed, and inserted into
the BglII/HindIII sites of pSUPER.retro.puro vector, following the
manufacturer’s instructions (Oligoengine, Seattle, WA). These con-
structs express a 19mer targeting two independent locations within
ATF3 mRNA or GFP (control shRNA) mRNA. A retroviral packag-
ing cell line (RetroPack PT67; Clontech Laboratories, Mountain View,
CA) was used for stable virus production according to the manu-
facturer’s instructions. Briefly, packaging cells were transfected with
ATF3-shRNA plasmid no. 1 or 2 or GFP-shRNA using FuGENE HD
(Roche). After generation of stable clones and determination of viral
titer, A549 cells were infectedwith viral supernatant using 4 μg/ml poly-
brene. Stable transfected clones expressing shRNAwere selected using
3 μg/ml puromycin.
Western Blot Analysis
Cells plated at 0.7 × 106 per 60-mm dish were allowed to grow over-
night and treated with the indicated drug for 24 hours. Protein samples
were collected in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM
sodium chloride, 1 mM EDTA, 1% Triton X-100, 0.25% sodium de-
oxycholate, 0.1% SDS) containing 50 mM sodium fluoride, 1 mM
sodium orthovanadate, 10 mM β-glycerophosphate, and 1× protease
inhibitor cocktail (Sigma). Protein concentrations were assayed using
a protein assay (Bio-Rad, Mississauga, Ontario, Canada) and a spectro-
photometer (Biomate 3; Thermo Fisher Scientific,Waltham,MA). Pro-
tein extracts representing 60 μg were separated on a 12% SDS-PAGE
gel and electrophoretically transferred to a polyvinylidene difluoride
membrane (Immobilon-P; Millipore, Billerica, MA). Membranes were
blocked in 5% skim milk powder in Tris-buffered saline containing
10% Tween-20 (TBS-T) for 1 hour at room temperature followed by
incubation with primary antibody diluted in 5% skim milk in TBS-T
with shaking overnight at 4°C. Polyclonal antibody ATF3, ERK,
and phospho-ERK (Tyr204) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Monoclonal antiactin was purchased
from Sigma-Aldrich, and monoclonal anti-p53 (Ab-6) was from Calbio-
chem (San Diego, CA). Polyclonal antibodies Jun, phospho-Jun (Ser73),
p38, phospho-p38 (Thr180/Tyr182), and poly (ADP-ribose) polymer-
ase (PARP) were purchased from Cell Signaling Technology (Beverly,
MA). Polyclonal antibodies against heat shock protein 27 (hsp27) and
phospho-hsp27 (Ser78) were purchased from Stessgen (Ann Arbor,
MI). After washing in TBS-T, blots were incubated with the appropri-
ate HRP-labeled secondary antibody for 1 hour at room temperature.
Visualization of protein bands was performed using the SuperSignalWest
Pico Chemiluminescent Substrate (Pierce, Rockford, IL) exposed on a
film (Kodak, Toronto, Canada) in a tabletop processor (SRX-101A;
Konica Minolta, Mississauga, Canada).
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
MCF-7 cells plated at 0.8 × 106 cells per 10-cm dish were incubated
at 37°C overnight. The next day, cells were treated with cisplatin, in
the absence or presence of the three MAPK inhibitors used in this
study, for 24 hours. Total RNA was extracted from cell samples using
the RNeasy Kit (Qiagen, Mississauga, Canada). RNA concentrations
were quantified using a spectrophotometer (ND-1000; NanoDrop
Technologies, Inc, Wilmington, DE). One microgram of total RNA
was reverse-transcribed to complementary DNA for quantitative real-
time reverse transcription–polymerase chain reaction (RT-PCR) as pre-
viously described [30]. The AB 7500 real-time RT-PCR system (Applied
Biosystems, Foster City, CA) was used to detect amplification. The real-
time PCRwas carried out in a total volume of 25μl that contained 2.5μl
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of synthesized complementary DNA (42 ng), 1.25 μl of TaqMan Gene
Expression Assay Primer/Probe (20×; ATF3, HS00231069; Applied
Biosystems), 12.5 μl of TaqMan Universal PCR Master Mix (2×;
4304437; Applied Biosystems), and 8.75 μl of RNase-free water for
ATF3 expression. The endogenous control for ATF3 was the house-
keeping gene, human GAPDH (20×; HS4333764-F; Applied Biosys-
tems). Amplification conditions were 95°C for 5 minutes and 40 PCR
cycles at 95°C for 15 seconds and at 60°C for 1 minute. Three inde-
pendent experiments were performed to determine the mean and SD of
gene expression.
Results
Cisplatin and Carboplatin Cytotoxicity Is Associated with
ATF3 Induction
We analyzed the cytotoxic effects of cisplatin and carboplatin treat-
ment on a number of human tumor cell lines, MCF-7 (breast adeno-
carcinoma), A549 (lung carcinoma), SKOV-3 (ovarian carcinoma), PC3
(prostate carcinoma), and A2780-cp (ovarian carcinoma), using the
MTT cell viability assay and flow cytometry (Figure 1). In A549, PC3,
and A2780-cp cell lines, higher doses of cisplatin lead to 100% cyto-
toxicity (Figure 1A), whereas the MCF-7 and SKOV-3 cell lines seemed
more resistant as determined by the MTT cell viability assay. Resistance
to the cytotoxic effects of cisplatin in the MCF-7 and SKOV-3 cell lines
was evidenced by a plateau patterning at higher doses of the treatment, a
pattern previously suggested to be related to deficiency in proapoptotic
factors [2] (Figure 1A). Indeed, theMCF-7 cell line is caspase-3–deficient
[31]. Therefore, the observed resistance to cisplatin in the MCF-7 cell
line may be mediated by a blockage in downstream apoptotic pathways
in which the platinum-based drug acts. Carboplatin also induced cell
cytotoxicity in all cell lines where MCF-7, SKOV-3, and PC3 cell lines
displayed the greatest resistance to the cytotoxic effects (Figure 1B). In-
terestingly, SKOV-3 and PC3 cell lines are functionally null for the tumor
suppressor p53, which may contribute to their resistance. As expected,
carboplatin was less cytotoxic at the same concentrations compared with
cisplatin treatment. We further used flow cytometry analyses to deter-
mine the potential for apoptosis induction by the platinum-based che-
motherapeutics in the A549 and SKOV-3 cell lines. Apoptosis was
visualized as a sub-2N peak that identifies apoptotic bodies resulting
from cellular fragmentation [32,33]. Cisplatin treatment (10 μg/ml for
48 hours) resulted in 10.19% and 8.42% of cells in the sub-2N fraction
in A549 and SKOV-3 cell lines, respectively (Figure 1C). Differences be-
tween percentage of apoptotic cells observed between MTT assay and
flow cytometry assay are largely due to the qualitative nature for the flow
cytometrymethod [33]. Carboplatin treatment (270μg/ml for 48 hours)
resulted in 23.44% and 11.33% of cells in sub-2N inA549 and SKOV-3
cell lines, respectively (data not shown).
Previously, our laboratory had identified lovastatin, a potent inhibitor
of mevalonate synthesis, as an inducer of the ISR pathway and sub-
sequent mediator of lovastatin-induced apoptosis [34]. Downstream
effectors of the ISR pathway activated by lovastatin included members
of the activating transcription factor (ATF) family, ATF4 and ATF3. A
role for the stress-inducible gene, ATF3, in tumorigenesis has been dem-
onstrated and can act either as a tumor suppressor or as an oncogene
depending on cell context. Because various stress pathways that induce
ATF3 expression have also been shown to regulate cytotoxicity, we first
evaluated the potential of cisplatin and carboplatin to affect ATF3 ex-
pression. Indeed, we found that ATF3 was significantly induced at the
protein level when treated for 24 hours with cytotoxic concentrations of
cisplatin (10 μg/ml) and carboplatin (270 μg/ml) in a panel of human
cancer cell lines (Figure 2A). These higher concentrations of drug treat-
ment induced significant cytotoxicity at 48-hour treatments as demon-
strated byMTTassay analysis in all cell lines evaluated (Figure 1A). The
noncytotoxic doses of each drug tested (cisplatin, 1 μg/ml; carboplatin,
2.7 μg/ml) produced either a weak or an undetectable induction of
ATF3 (Figure 2A). Immunocytochemical analysis of ATF3 expression
in cisplatin (8μg/ml)-treatedMCF-7 and PC3 cells for 24 hours showed
that, although untreated cells did not express ATF3, a significant pro-
portion of cisplatin-treated cells showed expression and nuclear localiza-
tion of this transcription factor (Figure 2B). Time course analysis of
ATF3 induction by cisplatin (10 μg/ml) and carboplatin (270 μg/ml)
revealed maximal induction levels occurring at 12 and 24 hours in the
MCF-7 cell line (Figure 2C ). Furthermore, this cytotoxic cisplatin dose
could specifically induce the levels of ATF3 mRNA (Figure 2D). In
summary, ATF3 is highly induced at the protein and mRNA levels by
cytotoxic doses of these agents in human cancer–derived cell lines.
Induction of ATF3 by Cisplatin Is Independent of a p53,
BRCA1, or ISR Mechanism
ATF3 mRNA and protein levels are readily induced by a wide range
of stress causing agents [9]. The mechanism(s) of stress-induced ATF3
has been previously well documented (Figure 3A), and in this study, we
evaluated these regulatory mechanisms with respect to cisplatin induc-
tion of ATF3. Because the tumor suppressor p53 had been previously
implicated in ATF3 regulation [22,23], we determined its role in cis-
platin induction of ATF3. ATF3 was induced by cisplatin in the p53
functionally null cell lines SKOV-3 and PC3, which suggested a p53-
independent mechanism (Figure 1A). To further investigate a possible
regulatory role, we virally expressed p53 in the PC3 cell line, treated the
cells with cisplatin or taxol, a microtubule-depolarizing agent, and deter-
mined ATF3 expression levels. ATF3 induction by cisplatin (10 μg/ml
for 24 hours) was unchanged between LacZ vector control and p53-
containing viral infection under cisplatin treatment, further confirming
a p53-independent mechanism (Figure 3B, middle panel ). Taxol treat-
ment (25 μM for 24 hours) had no effect on ATF3 expression levels
(Figure 3B, bottom panel ). We next looked at the possible involvement
of the DNA damage response factor, BRCA1, in the regulation of ATF3
induction by platinum-based chemodrugs because previous reports
suggested that BRCA1 could transcriptionally regulate ATF3 expression
[17,24]. To determine whether BRCA1 played a role in ATF3 induction
by cisplatin or carboplatin, ATF3 induction was contrasted in the breast
adenocarcinoma cell lines expressing and null for BRCA1, MCF-7, and
1937, respectively. As previously demonstrated [35], we also confirmed
the differential expression of BRCA1 in these cell lines and also showed
that 1937 cells are sensitive to cisplatin and carboplatin at the higher
cytotoxic doses used (data not shown). As shown in Figure 3C , no dif-
ference in ATF3 induction levels was observed between the two cell
lines with either treatment, suggesting that induction of ATF3 by the
chemodrugs is independent of BRCA1 expression. Next, we evaluated
the role of the ISR pathway inmediating ATF3 induction because ATF3
is a downstream effector of the pathway [25]. We tested the ability of
cisplatin and carboplatin to induce ATF3 expression in immortalized
heterozygous or ATF4 null MEFs, the upstream inducer of ATF3 ex-
pression in the ISR pathway. Figure 3D demonstrates the absence of
ATF4 had no affect on ATF3 induced by cisplatin and carboplatin,
suggesting an ISR independent mechanism as well. Lower induction
levels of ATF3 in the ATF4 MEFs compared with cell lines analyzed
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in Figure 2A is likely due to the lower doses of drug used (cisplatin, 1 μg/
ml; carboplatin, 2.7 μg/ml) owing to the enhanced sensitivity of these
MEFs to their cytotoxicity.
MAPK Pathways Regulate ATF3 Induction by Cisplatin
Recent characterization of ATF3 induction by anisomycin, an antibiotic
that activates multiple signaling pathways, revealed a MAPK-dependent
mechanism [27]; therefore, we investigated the individual MAPK path-
ways for potential regulation of ATF3 expression by platinum-based
chemodrugs. First, we determined whether the pathways were activated
under the drug treatments in the MCF-7 cell line. Time course analysis
of JNK pathway activation after treatment with platinum-based chemo-
drugs as measured by the phosphorylation status of c-Jun, a downstream
effector of the JNK pathway cascade, revealed a slight increase in phospho-
c-Jun at 12 and 24 hours, which coincided with the maximal ATF3
induction by both cisplatin and carboplatin (Figure 4A, left panel ). To
determine the role of the JNK pathway in ATF3 induction by cisplatin
Figure 1. Cisplatin and carboplatin treatment induce cytotoxicity and apoptosis in a panel of human cancer cell lines. Cell lines SKOV-3,
MCF-7, A2780-cp, PC3, and A549 were treated with cisplatin (A) or carboplatin (B) for 48 hours, and cell viability was assessed as measured
by MTT activity. Data are represented as a percentage of MTT activity where untreated cells were taken to be 100%. Error bars are repre-
sentative of six individual treated samples. (C) Flow cytometry analysis of SKOV-3 and A549 cell lines treated with cisplatin for 48 hours.
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(10 μg/ml) and carboplatin (270 μg/ml), MCF-7 cells were treated with
cisplatin or carboplatin for 24 hours in the presence of a JNK-specific
inhibitor, JNK inhibitor II SP600125 (SP), which inhibited this path-
way asmeasured by phospho-c-Jun levels (Figure 4A, right panel ). ATF3
induction levels were found to be reduced under cisplatin treatment in
the presence of JNK inhibitor, but not with carboplatin, inMCF-7 cells
(Figure 4A, right panel).
Next, we evaluated the role of the ERK pathway in ATF3 induction
by cisplatin and carboplatin. Time course treatment with chemodrugs
revealed activation of the ERK pathway, as measured by the phosphory-
lation status of ERK, at 4 hours under cisplatin, and 4 and 8 hours under
carboplatin treatment (Figure 4B, left panel ). Phosphorylated ERK
was not detected at 12 and 24 hours under either treatment (Figure 4A,
left panel ). To determine the role of the ERK pathway in ATF3 induc-
tion by cisplatin and carboplatin, MCF-7 cells were treated with cis-
platin or carboplatin in the presence of the specific inhibitor to the
ERK pathway, UO126, which was effective in blocking of the pathway
as measured by phospho-ERK levels (Figure 4B, right panel ). Treatment
with ERK inhibitor in the presence of cisplatin and carboplatin revealed
a dose-dependent decrease in ATF3 expression levels, suggesting a role
for the pathway in mediating induction by the chemodrugs (Figure 4B,
right panel ).
Lastly, we determined the activation of the p38 pathway in MCF-7
cells after treatment with cisplatin or carboplatin at 9- and 24-hour time
points. Indeed, it was observed that the pathway was active at these time
points as measured by the phosphorylation status of p38, which corre-
lated with ATF3 induction levels (Figure 4C , left panel ). To investigate
the role of p38 pathway in the induction of ATF3 by cisplatin and car-
boplatin, MCF-7 cells were treated with chemodrugs in the presence of
the specific p38 inhibitor, SB203580 (SB), for 24 hours. This p38 in-
hibitor was shown to effectively block the pathway as measured by the
phosphorylation status of hsp27, a downstream target of p38 (Fig-
ure 4C , right panel ). ATF3 expression levels were also shown to be de-
creased by the inhibitor in a dose-dependent manner suggesting a
regulatory role of the p38 pathway in chemodrug induction of ATF3
(Figure 4C , right panel ). Similarly, inhibition of the p38 pathway also
resulted in the effective blockage of the ATF3 induction by cisplatin
and carboplatin in the PC3 cell line (Figure 4D).
We similarly characterized the involvement of the MAPK pathways
in cisplatin-induced ATF3 expression in the tumor-derived cells lines
SKOV-3, MCF-7, PC3, and A459. These inhibitors against the three
MAPK pathways evaluated had variable degrees of inhibition of ATF3
induction by cisplatin (10 μg/ml for 24 hours), implicating all three
pathways in the mechanistic induction of ATF3 by cisplatin (Fig-
ure 5A). Interestingly, the pattern of reduced ATF3 induction by cis-
platin in the presence of MAPK inhibitors was consistent between
all four cancer cell lines, with the p38 pathway inhibitor showing
the greatest inhibition of ATF3 induction and the ERK pathway
Figure 2. ATF3 is induced by cisplatin and carboplatin. (A) ATF3 pro-
tein expression levels after treatment with low and cytotoxic doses
of cisplatin (1 and 10 μg/ml) and carboplatin (27 and 270 μg/ml) in
SKOV-3, MCF-7, PC3, A2780-cp, and A549 cell lines. (B) Immuno-
cytochemistry analysis of ATF3 expression (brown) in MCF-7 and
PC3 cell lines in nontreated cells (control) and cisplatin treatment for
24 hours. Methylene blue stain is used as a nuclear counterstain. (C)
Time course analysis of ATF3 expression in MCF-7 cells treated with
cisplatin (10 μg/ml) or carboplatin (270 μg/ml) at the 4-, 8-, 12-, and
24-hour time points. (D) ATF3 mRNA quantified by RT-PCR in MCF-
7 cells untreated, treated with 2 and 10 μg/ml cisplatin for 24 hours.
Error bars are representative of quantifiedmRNA from three indepen-
dent experiments. In all blots, actin is used as a loading control.
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inhibitor showing the least (Figure 5A). To determine whether the
MAPK pathway inhibitors used in this study were specific, cisplatin-
induced (10 μg/ml for 24 hours) activation of each pathway in the pres-
ence of these specific inhibitors was assessed. MCF-7 cells were treated
with cisplatin alone, or in combination with JNK pathway inhibitor,
SP600125 (50 μM), ERK inhibitor, UO126 (25 μM), or p38 pathway
inhibitor, SB203580 (10 μM), and activation of the pathways was as-
sessed by phosphorylation status of c-jun (JNK pathway), ERK, and
hsp27 (p38 pathway; Figure 5B). Each pathway was inhibited by its re-
spective inhibitor without significantly affecting the activation of the
other pathways confirming their specificity (Figure 5B). We also dem-
onstrate that the coadministration of all three MAPK inhibitors used in
this study could downregulate 10μg/ml cisplatin-induced ATF3 expres-
sion at the mRNA level in a pattern of inhibition that was similar to that
observed at the protein level at 24 hours (Figure 5C).
To further define the role of the p38 pathway in ATF3 induction by
cisplatin, the MCF-7 cell line was transiently transfected with various
p38 constructs (WT, DN, and CA) for 24 hours followed by no treat-
ment (left panel ) or 10 μg/ml cisplatin in the absence or presence of
10 μM SB203580 (right panel ), for an additional 24 hours. Untrans-
fected (control) and a β-galactosidase–expressing plasmid were used
as negative controls (Figure 5D). In untreated samples, activation of
the pathway as measured by phospho-hsp27 was highest in p38-CA–
transfected cells and lowest in the p38-DN–transfected cells, confirm-
ing functionality of the constructs. ATF3 expression levels were also in-
creased on p38-CA transfection, suggesting that activation of the p38
pathway is sufficient to induce ATF3 expression (Figure 5D, left panel ).
After cisplatin treatment, phospho-hsp27 was induced, at greater
levels, which is consistent with activation of the pathway by the drug
(Figure 4C , left panel ), where p38-DN–transfected cells decreased ex-
pression of both p-hsp27 and ATF3 as compared with p38-WT– and
p38-CA–transfected cells (Figure 5D, right panel ). Cisplatin treatment
in the presence of the p38 inhibitor resulted in the abolishment of
phospho-hsp27 and ATF3 expressions irrespective of transfection status
(Figure 5D, right panel ). These data provide further evidence that
ATF3 induction by cisplatin is mediated through MAPK pathway
activation. Taken together, these results identify the MAPK pathways
as regulators of ATF3 induction by platinum-based cytotoxic drugs.
Figure 3. ATF3 induction by cisplatin is independent of a p53, BRCA1, and ISR mechanism. (A) Schematic representation of the potential
mechanisms involved in ATF3 induction by cisplatin. (B) ATF3 detection in PC3 cells transduced with no virus (mock), LacZ vector control
(LacZ), or p53wt (p53) containing adenovirus for 6 hours after no treatment (control; top panel) or after treatment with cisplatin (10 μg/ml;
middle panel) or taxol (25 μM; bottom panel) for 24 hours. (C) ATF3 expression detected in MCF-7 and 1937 (BRCA1 null) cells untreated
(control) or treatedwith cisplatin (1 and 10μg/ml) or carboplatin (27 and 270 μg/ml) for 24 hours. (D) ATF3detection inATF4−/− andATF4+/−
MEFs untreated (control) or treatedwith cisplatin (1 μg/ml) and carboplatin (27 μM) for 24 hours. In all blots, actin is used as a loading control.
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Figure 4. ATF3 induction by cisplatin is mediated by MAPK pathways in MCF-7 cells. (A) MCF-7 cells without treatment (control) and those
treated with anisomycin (20 μM) for 1 hour and cisplatin (10 μg/ml) or carboplatin (270 μg/ml) for the 4-, 8-, 12-, and 24-hour time points were
analyzed by Western blot analysis for the detection of ATF3, actin, phospho-c-jun (p-c-jun), and total c-jun (left panel). MCF-7 cells similarly
treated with cisplatin or carboplatin in the absence (0) or presence of JNK pathway inhibitor (SP; 25 and 50 μM) for 24 hours were analyzed
for the detection of ATF3, actin, p-c-jun, and total c-jun (right panel). (B) MCF-7 cells without treatment (control) and those treated with
anisomycin (20 μM) for 1 hour and cisplatin or carboplatin as previously mentioned for the 4-, 8-, 12-, and 24-hour time points were analyzed
byWestern blot analysis for the detection of ATF3, actin, phospho-ERK (p-ERK), and total ERK (left panel). MCF-7 cells treated with cisplatin
or carboplatin in the absence (0) or presence of ERK pathway inhibitor (UO126; 10 and 25 μM) for 24 hourswere analyzed for the detection of
ATF3 and actin and at 4 hours for p-ERK and total ERK (right panel). (C) MCF-7 cells untreated (control), treated with tumor necrosis factor α
(20 ng/ml) for 15 and 30 minutes, and cisplatin or carboplatin for the 9- and 24-hour time points were analyzed by Western blot analysis for
the detection of ATF3, actin, phospho-p38 (p-p38), and total p38 (left panel). MCF-7 cells treated with cisplatin or carboplatin in the absence
(0) or presence of p38 inhibitor, SB203580 (SB; 5 and 10 μM), for 24 hours were analyzed for the detection of ATF3, actin, phospho-hsp27
(p-hsp27), and total hsp27 (right panel). (D) PC3 cells treated with cisplatin (10 μg/ml) or carboplatin (270 μg/ml) in the absence (0) or pres-
ence of p38 inhibitor, SB203580 (SB; 5 and 10 μM), for 24 hours were analyzed for the detection of ATF3, actin, phospho-hsp27 (p-hsp27),
and total hsp27.
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ATF3 Regulates, in Part, the Cytotoxic Effects of Cisplatin
Because ATF3 has been previously shown to play a proapoptotic
role in cancer models, we investigated the role of ATF3 induction by
cisplatin in regulating the cytotoxic effects of cisplatin. Treating A549
cells with increasing concentrations of cisplatin in the presence or ab-
sence of SP600125 (50 μM), U0126 (25 μM), or SB203580 (10 μM),
the cytotoxic effects of cisplatin (48 h) was observed to be attenuated by
approximately 20% as determined by the MTT cell viability assay (Fig-
ure 6A). Similar results were obtained in the PC3 cell line for the
SB203580 inhibitor (data not shown). To further demonstrate ATF3’s
role as a factor in the cytotoxic effects of cisplatin, the stable expression
of shRNA against two different sequences of the ATF3-mRNA and to
green fluorescent protein (GFP) as a negative control was used in the
A549 cell line. Cells expressing both shATF3 and treated with cisplatin
showed similar attenuation (20%) of the cytotoxic effects of the drug in
the shATF3 cell lines as compared with shGFP control as determined
by MTTanalysis (Figure 6B). The cleavage status of PARP, a marker of
apoptosis, was determined in the A549 cell line after treatment with
cisplatin (10 μg/ml for 24 hours) in the presence or absence of the
MAPK inhibitors at the previously mentioned concentrations. Indeed,
PARP cleavage induced by cisplatin was reduced in the presence of
MAPK inhibitors to all three pathways (Figure 6C ), correlating with
the attenuated cytotoxicity observed in Figure 6A. Likewise, reduced
PARP cleavage was also observed in the shATF3 (shATF31 and
shATF32) compared with the GFP control cell line (Figure 6D).
Lastly, we contrasted the cytotoxic effects of increasing cisplatin treat-
ments on MEF cells expressing and knocked out for ATF3. ATF3+/+
MEFs were more sensitive to cytotoxic effects of cisplatin compared
with ATF3−/− MEFs (Figure 6E). Cisplatin treatment induced ATF3
expression in the ATF3+/+ MEFs but not in the ATF3−/−MEFs (Fig-
ure 6E , inset). The differences in cytotoxic effects of cisplatin observed
in ATF3+/+ and ATF3−/− MEFs were contrasted in MEFs (+/+) and
(−/−) for the ATF2 family member. No differences in the effect of cis-
platin cytotoxicity were observed between ATF2+/+ and ATF2−/−
Figure 5. Induction of ATF3 by cisplatin ismediated byMAPK pathways in a panel of human cancer cells. (A) SKOV-3, MCF-7, PC3, and A549
cells untreated and treatedwith cisplatin (10 μg/ml) for 24 hours in the absence (control) or presence ofMAPK pathway inhibitors (SP600125
[50 μM], UO126 [25 μM], and SB203580 [10 μM]) and analyzed by Western blot analysis for ATF3 and actin. (B) MCF-7 cells treated with
cisplatin (10 μg/ml) for 24 hours in the absence (control) or presence of MAPK pathway inhibitors (SP600125 [50 μM], UO126 [25 μM],
and SB203580 [10 μM]) and analyzed byWestern blot analysis for p-c-jun, c-jun total, p-ERK, ERK total, p-hsp27, hsp27 total, ATF3, and actin.
(C) ATF3mRNA quantified by RT-PCR in MCF-7 cells untreated or treated with cisplatin (10 μg/ml) or cisplatin in the presence of SP (50 μM),
UO126 (25 μM), and SB (10 μM) for 24 hours. Error bars are representative of three independent experiments. (D) MCF-7 cells transiently
transfected with 2 μg of β-galactosidase (β-gal), p38-WT, p38-DN, and p38-CA, for 24 hours followed (left panel) by no treatment or by treat-
ment with cisplatin (10 μg/ml) alone or in combination with p38 inhibitor, SB (10 μM), for an additional 24 hours (right panel) and analyzed by
Western blot analysis for ATF3, actin, p-hsp27, and hsp27 total.
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MEFs (Figure 6F ). In all three models where ATF3 expression was
targeted, there was approximately a two-fold increase in cisplatin dose
required for 50% cytotoxicity. Taken together, this study provides evi-
dence that the cytotoxic effects invoked by cisplatin can in part be cor-
related to the drug’s ability to induce ATF3 expression as regulated by
MAPK pathways.
Discussion
In summary, this study has identified the platinum-based chemocyto-
toxic drug, cisplatin, as an inducer of the stress-inducible gene, ATF3,
at both the mRNA and protein levels. Through elimination of potential
ATF3-regulatorymechanisms, namely, p53, BRCA1, and ISR, we iden-
tified ATF3 induction by cisplatin as regulated by the MAPK pathways
JNK, ERK, and p38. Inhibition of the MAPK pathway with the p38
inhibitor SB203580 in cisplatin-treated cells resulted in the greatest de-
crease in ATF3 induction at the protein level in the human cancer cells
analyzed. Increased ATF3 expression was associated with cisplatin-
induced cytotoxicity as evidenced by attenuation of ATF3 expression
and cytotoxicity with treatment of the three MAPK pathway inhibitors
and in shATF3 knockdown cells compared with control. Targeting the
Figure 6. ATF3 expression mediates, in part, the cytotoxic effects of cisplatin. (A) A549 cells treated with cisplatin (0-10 μg/ml) in the pres-
ence or absence of 50 μMSP600125, 25 μMUO126, and 10 μMSB203580 for 48 hours were assessed for cell cytotoxicity as measured by
MTT activity. (B) A549 cells stably expressing shRNA against two separate ATF3mRNA regions (shATF3-1 and shATF3-2) and GFP (negative
control) were treated with cisplatin for 48 hours and were analyzed for MTT activity. For A and B, data are presented as a percentage of MTT
activity where untreated cells were taken to be 100%. Error bars are representative of six independently treated samples. (C) A549 cells
without treatment (untreated) or treated with 10 μg/ml cisplatin for 24 hours in the presence of MAPK inhibitors of 50 μMSP600125, 25 μM
UO126, and 10 μM SB203580 and analyzed by Western blot analysis for PARP and actin as a loading control. (D) GFP-, shATF3-1–, and
shATF3-2–expressing cell lines treated with or without 10 μg/ml cisplatin for 24 hours and analyzed byWestern blot analysis for PARP, ATF3,
and actin expression. (E) ATF3−/− and ATF3+/+MEFs treatedwith cisplatin (0-8 μg/ml) and analyzed forMTT activity. Western blot analysis
for ATF3 and actin in ATF3−/− and ATF3+/+ MEFs treated with 10 μg/ml of cisplatin for 24 hours (inset). Actin was used as a loading
control. (F) ATF2−/− and ATF2+/+ MEFs treated with cisplatin (0-8 μg/ml) and analyzed for MTT activity.
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activity of p38 with the expression of wild type, DN and CA expression
constructs alsomodulated cisplatin-inducedATF3 expression as theDN
version attenuated cisplatin-induced ATF3 expression. Furthermore,
ATF3−/−MEFs were more resistant to cisplatin cytotoxicity compared
with ATF3+/+ MEFs. Taken together, these results provide strong evi-
dence that ATF3 is a regulator of platinum-based chemotherapeutic-
induced cytotoxicity. Identifying ATF3 as a cisplatin-induced gene
through MAPK pathway activation may have therapeutic relevance.
Inducers of the MAPK pathways or other cell stress pathways that en-
hance ATF3 expression may augment the cytotoxic effects of cisplatin.
For example, two agents that induce ATF3 expression through different
mechanisms, salubrinal and proteosome inhibitors, have demonstrated
synergistic cytotoxicity inmyeloma cells andmay represent a novel com-
binational therapeutic approach [36,37].
It is well characterized that the commencement of the anticancer ef-
fects of cisplatin involves DNA adduct formation resulting in apoptotic
cell death if the DNA damage cannot be adequately repaired [1]. How-
ever, the specific mechanism(s) downstream of cisplatin-induced DNA
damage, which leads to the apoptotic response, are poorly defined. In
this study, we show that cisplatin and its derivative, carboplatin, could
readily induce ATF3 expression. A role for ATF3 in tumorigenesis has
been implicated through its ability to affect the transcription of a num-
ber of regulators of apoptosis and cell proliferation includingCHOPand
cyclinD1, respectively [38,39]. Depending on the cell type and the type
and severity of the cell stressor, ATF3 has been implicated as both a
proto-oncogene or tumor suppressor. For example, overexpression of
ATF3 inhibited proliferation and induced cell cycle arrest in human
cancer cells [17], whereas loss of ATF3 in a Ras-transformed model re-
sulted in higher proliferation rates and increased G1- to S-phase transi-
tion efficiency [18]. Treating our panel of human cancer cell lines with a
high and a low dose of cisplatin or carboplatin revealed an increase in
ATF3 protein expression that was associated with the high cytotoxic
doses of these drugs, implicating a role for ATF3 in regulating platin-
induced cytotoxicity. Because ATF3 has been implicated as a biomarker
for cell death in cancer models [16–19,40], based on these results, ex-
pression levels of ATF3with respect to platin response in patients should
be evaluated.
After the identification ofATF3 as a cisplatin-induced gene, themajor
objective of this study was to systematically identify the mechanism of
induction of ATF3. A number of cellular stress pathways have been
shown to regulate the expression of ATF3. The DNA damage response
factors p53 and BRCA1 had previously been linked to ATF3 regulation.
Likewise, ATF3 is a known downstream effector of the ISR induced by
ER, hypoxia, and viral and metabolic stressors [25]. This study showed
that BRCA1, p53, and ISR are not factors in ATF3 induction by cis-
platin. Instead, the mechanism of induction of ATF3 by cisplatin was
found to be largelyMAPK pathway–dependent. Looking at the involve-
ment of the ERK, JNK, and p38 pathways, we found that all three path-
ways, when inhibited, lead to decreased induction of ATF3 by cisplatin.
Although the inhibition of ATF3 induction by cisplatin in the presence
of MAPK pathway inhibitors was significant, it was not complete sug-
gesting that other regulatory mechanism(s) may exist.
In conclusion, we determined the functional relevance of ATF3 ex-
pression in regulating cisplatin-induced cytotoxicity. Recent literature
has implicated the MAPK pathways in the regulation of stress-induced
ATF3 apoptosis. Similar to our results, that ribotoxic stress induction of
ATF3 was shown to be mediated through the p38 pathway, and ATF3
expression was shown as a proapoptotic factor in HeLa cells [27].
Another recent study reported that cisplatin could induce ATF3 in
T98G glioblastoma cells at both the protein and mRNA levels [26].
In contrast to our results, this report showed that the induction of
ATF3 by cisplatin was antiapoptotic. Discrepancies between our re-
sults and others could stem from differences in cellular model or status
of cell line malignancy both of which have previously been suggested
to determine ATF3’s role as an antiapoptotic or a proapoptotic fac-
tor [18,19].
The literature has previously reported that cisplatin treatment results
in the activation of MAPKs [41]. Reports showing activation of the p38
pathway by cisplatin has been exclusively correlated with proapoptotic
outcomes in a number of cell lines, whereas activation of the JNK and
ERKpathways is correlated with both anti-death and pro-death outcomes
[41]. Inhibition of the p38 pathway with specific inhibitors has been
previously shown to increase resistance to cisplatin [42,43]. Likewise,
reduced activation of the p38 pathway has been identified as a mecha-
nism correlated with cisplatin resistance [2]. Although the activation of
MAPK pathways by cisplatin treatment has been documented, the sig-
naling pathways downstream of activation that determines cell fate are
poorly understood. This study identifies ATF3, previously defined as a
factor capable of influencing cellular fate, as a novel target of the MAPK
pathways when activated by cisplatin treatment. This study suggests
that ATF3 induction by cisplatin may identify a novel factor responsible
for mediating the established link between cisplatin-induced MAPK
pathway activation and cell cytotoxic outcomes.Whether ATF3 is directly
activated by the MAPK pathway or is induced downstream of known
MAPK pathway transcription factor targets remains to be determined.
Defining the specific mechanism(s) responsible for the antitumor affects
of cisplatin may lead to novel and improved therapeutic approaches.
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